NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $85.31
  • Forecasted Upside: 24.41 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$68.57
▲ +0.45 (0.66%)
1 month | 3 months | 12 months
Get New Arrowhead Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARWR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARWR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$85.31
▲ +24.41% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Arrowhead Pharmaceuticals in the last 3 months. The average price target is $85.31, with a high forecast of $110.00 and a low forecast of $34.00. The average price target represents a 24.41% upside from the last price of $68.57.
Buy
The current consensus among 12 contributing investment analysts is to buy stock in Arrowhead Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2021CitigroupBoost Price Target$90.00 ➝ $110.00Medium
i
2/8/2021B. RileyBoost Price TargetBuy$98.00 ➝ $106.00High
i
2/5/2021Piper SandlerBoost Price TargetOverweight$90.00 ➝ $99.00High
i
2/5/2021Chardan CapitalBoost Price TargetBuy$81.00 ➝ $97.00High
i
2/5/2021HC WainwrightBoost Price TargetBuy$90.00 ➝ $95.00High
i
Rating by P. Trucchio at HC Wainwright
12/21/2020Robert W. BairdDowngradeOutperform ➝ Neutral$75.00High
i
12/15/2020UBS GroupInitiated CoverageBuy$95.00Low
i
11/24/2020Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$62.00 ➝ $80.00High
i
11/24/2020Cantor FitzgeraldBoost Price TargetOverweight$58.00 ➝ $80.00High
i
11/24/2020SVB LeerinkLower Price TargetMarket Perform$35.00 ➝ $34.00High
i
11/19/2020Smith Barney CitigroupInitiated CoverageBuy$90.00Low
i
11/19/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageBuy$90.00Low
i
11/17/2020B. RileyBoost Price TargetBuy ➝ Positive$68.00 ➝ $98.00Low
i
11/16/2020Robert W. BairdBoost Price TargetOutperform$70.00 ➝ $75.00Low
i
10/12/2020B. RileyBoost Price Target$57.00 ➝ $68.00Low
i
Rating by Mayank Mamtani at B. Riley
10/12/2020HC WainwrightReiterated RatingBuyLow
i
Rating by P. Trucchio at HC Wainwright
10/8/2020Piper SandlerBoost Price Target$80.00 ➝ $90.00High
i
9/17/2020SVB LeerinkBoost Price TargetMarket Perform$29.00 ➝ $31.00Low
i
Rating by M. Foroohar at SVB Leerink LLC
8/24/2020HC WainwrightReiterated RatingBuyLow
i
Rating by P. Trucchio at HC Wainwright
7/29/2020Chardan CapitalReiterated RatingBuy$81.00High
i
Rating by Keay Nakae at Chardan Capital
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$62.00High
i
5/10/2020B. RileyReiterated RatingBuy$57.00High
i
Rating by Mayank Mamtani at B. Riley
5/8/2020Cantor FitzgeraldReiterated RatingBuy$60.00 ➝ $58.00High
i
Rating by A. Young at Cantor Fitzgerald
5/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$58.00High
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
4/15/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$55.00 ➝ $60.00High
i
Rating by A. Young at Cantor Fitzgerald
3/31/2020B. RileyReiterated RatingBuy$57.00High
i
Rating by Mayank Mamtani at B. Riley
3/24/2020SVB LeerinkUpgradeUnderperform ➝ Market Perform$29.00Medium
i
Rating by Mani Foroohar at SVB Leerink LLC
3/17/2020The Goldman Sachs GroupInitiated CoverageNeutral$45.00Medium
i
3/13/2020B. RileyLower Price TargetBuy$83.00 ➝ $57.00High
i
Rating by Mayank Mamtani at B. Riley
2/7/2020Jefferies Financial GroupBoost Price Target$77.00 ➝ $80.00Medium
i
2/6/2020B. RileyReiterated RatingBuy$83.00High
i
Rating by Mayank Mamtani at B. Riley
2/6/2020Cantor FitzgeraldBoost Price TargetNeutral$50.00 ➝ $55.00High
i
Rating by A. Young at Cantor Fitzgerald
1/24/2020B. RileyReiterated RatingBuy$83.00Low
i
Rating by Mayank Mamtani at B. Riley
1/21/2020SVB LeerinkInitiated CoverageUnderperform$32.00High
i
Rating by M. Foroohar at SVB Leerink LLC
12/12/2019OppenheimerInitiated CoverageHoldMedium
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
12/9/2019Piper Jaffray CompaniesBoost Price TargetOverweight$72.00 ➝ $80.00Medium
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/29/2019Chardan CapitalReiterated RatingBuy$45.00 ➝ $81.00Medium
i
11/27/2019B. RileyReiterated RatingBuy$59.00 ➝ $83.00High
i
Rating by Mayank Mamtani at B. Riley
11/26/2019S&P Equity ResearchReiterated RatingBuyMedium
i
11/26/2019Piper Jaffray CompaniesReiterated RatingOverweight$54.00 ➝ $72.00High
i
Rating by Edward Tenthoff at Piper Jaffray Companies
11/25/2019Robert W. BairdUpgradeNeutral ➝ Outperform$39.00 ➝ $70.00High
i
11/19/2019Cantor FitzgeraldReiterated RatingNeutral$24.00 ➝ $50.00Medium
i
Rating by A. Young at Cantor Fitzgerald
11/13/2019B. RileyBoost Price TargetBuy$46.00 ➝ $59.00Low
i
Rating by Mayank Mamtani at B. Riley
10/24/2019Robert W. BairdDowngradeOutperform ➝ Neutral$39.00High
i
10/22/2019Chardan CapitalBoost Price TargetBuy$32.00 ➝ $45.00High
i
10/21/2019B. RileySet Price TargetBuy$46.00High
i
Rating by Mayank Mamtani at B. Riley
10/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$50.00 ➝ $54.00Low
i
10/17/2019Cantor FitzgeraldReiterated RatingNeutralLow
i
Rating by A. Young at Cantor Fitzgerald
10/2/2019Robert W. BairdInitiated CoverageOutperform$39.00Medium
i
9/16/2019Piper Jaffray CompaniesReiterated RatingOverweight$50.00Medium
i
8/19/2019B. RileyBoost Price TargetBuy$32.00 ➝ $46.00High
i
Rating by Mayank Mamtani at B. Riley
8/6/2019Piper Jaffray CompaniesBoost Price TargetOverweight$33.00 ➝ $50.00Low
i
6/27/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$24.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
5/28/2019B. RileyBoost Price TargetBuy$26.00 ➝ $32.00Low
i
5/13/2019B. RileyBoost Price TargetBuy$19.00 ➝ $26.00High
i
4/16/2019Piper Jaffray CompaniesBoost Price TargetOverweight$25.00 ➝ $33.00Medium
i
4/12/2019Cantor FitzgeraldSet Price TargetBuy$24.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
2/11/2019Chardan CapitalReiterated RatingBuy$24.50High
i
Rating by Keay Nakae at Chardan Capital
12/17/2018Chardan CapitalReiterated RatingBuy$24.50Low
i
Rating by Keay Nakae at Chardan Capital
12/11/2018Cantor FitzgeraldSet Price TargetBuy$24.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
10/17/2018William BlairReiterated RatingOutperformMedium
i
10/14/2018Chardan CapitalSet Price TargetBuy$25.00Low
i
Rating by Keay Nakae at Chardan Capital
10/11/2018Cantor FitzgeraldReiterated RatingBuy$24.00Low
i
Rating by Justin Kim at Cantor Fitzgerald
10/4/2018Cantor FitzgeraldBoost Price TargetOverweight$18.00 ➝ $24.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
10/4/2018Piper Jaffray CompaniesReiterated RatingOverweight$25.00High
i
10/2/2018Cantor FitzgeraldSet Price TargetBuy$18.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
9/14/2018Jefferies Financial GroupBoost Price TargetPositive ➝ Buy$24.00Medium
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
9/6/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$17.50 ➝ $24.50Medium
i
Rating by Keay Nakae at Chardan Capital
9/6/2018B. RileyUpgradeNeutral ➝ Buy$18.00 ➝ $19.00High
i
Rating by M. Kumar at B. Riley
9/6/2018Cantor FitzgeraldSet Price TargetBuy$18.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
8/13/2018Chardan CapitalReiterated RatingBuy$17.50Medium
i
Rating by Keay Nakae at Chardan Capital
8/8/2018Cantor FitzgeraldReiterated RatingOverweight$13.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
8/8/2018Jefferies Financial GroupReiterated RatingBuy$20.00Low
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
8/8/2018B. RileyBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $18.00High
i
8/7/2018Cantor FitzgeraldSet Price TargetBuy$13.00 ➝ $18.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
8/1/2018Cantor FitzgeraldInitiated CoverageBuy$13.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
7/8/2018Chardan CapitalSet Price TargetBuy$16.00High
i
Rating by Keay Nakae at Chardan Capital
7/2/2018Chardan CapitalBoost Price TargetBuy$9.50 ➝ $16.00High
i
Rating by K. Nakae at Chardan Capital
6/29/2018Piper Jaffray CompaniesReiterated RatingOverweight$17.00Low
i
6/18/2018S&P Equity ResearchLower Price Target$13.76 ➝ $11.68Medium
i
6/18/2018Cantor FitzgeraldReiterated RatingBuy$13.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
5/30/2018Cantor FitzgeraldReiterated RatingBuy$13.00High
i
Rating by E. Piros at Cantor Fitzgerald
5/8/2018Piper Jaffray CompaniesBoost Price TargetOverweight$11.00High
i
5/8/2018Cantor FitzgeraldUpgradeNeutral ➝ Overweight$13.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
3/27/2018Jefferies Financial GroupInitiated CoverageBuy$10.00High
i
2/19/2018Chardan CapitalReiterated RatingBuy$7.00Low
i
Rating by K. Nakae at Chardan Capital
2/12/2018B. RileyBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.00Medium
i
Rating by M. Kumar at B. Riley
2/12/2018Cantor FitzgeraldSet Price TargetNeutral ➝ Neutral$2.00 ➝ $5.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
1/16/2018Chardan CapitalReiterated RatingNeutralMedium
i
Rating by K. Nakae at Chardan Capital
1/5/2018B. RileyInitiated CoverageNeutral ➝ Neutral$3.00Medium
i
Rating by M. Kumar at B. Riley
12/12/2017Cantor FitzgeraldSet Price TargetHold$2.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
11/27/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$5.50High
i
9/25/2017Cantor FitzgeraldReiterated RatingHold$2.00Medium
i
9/18/2017William BlairUpgradeMarket Perform ➝ OutperformHigh
i
Rating by Y. Xu at William Blair
9/15/2017Cantor FitzgeraldReiterated RatingHold$1.00 ➝ $2.00High
i
9/13/2017Chardan CapitalReiterated RatingNeutralMedium
i
Rating by G. Amusa at Chardan Capital
8/4/2017Jefferies Financial GroupReiterated RatingHold$2.00High
i
7/28/2017Piper Jaffray CompaniesReiterated RatingHold$2.00Medium
i
4/12/2017Jefferies Financial GroupReiterated RatingHold$2.00Low
i
11/30/2016Jefferies Financial GroupReiterated RatingHold$5.00 ➝ $2.00N/A
i
11/30/2016William BlairDowngradeOutperform ➝ Market Perform$12.00 ➝ $2.00N/A
i
Rating by Y. Xu at William Blair
11/30/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$10.00 ➝ $2.00N/A
i
11/30/2016Cantor FitzgeraldDowngradeBuy ➝ Hold$15.00 ➝ $1.00N/A
i
Rating by elemer piros at Cantor Fitzgerald
11/30/2016Chardan CapitalDowngradeBuy ➝ Neutral$8.00 ➝ $2.00N/A
i
Rating by Madhu Kumar at Chardan Capital
11/10/2016Cantor FitzgeraldReiterated RatingBuy$15.00N/A
i
Rating by elemer piros at Cantor Fitzgerald
11/10/2016Jefferies Financial GroupLower Price TargetHold$6.50 ➝ $5.00N/A
i
11/10/2016Chardan CapitalLower Price TargetBuy$10.00 ➝ $8.00N/A
i
Rating by Madhu Kumar at Chardan Capital
9/29/2016Chardan CapitalSet Price TargetBuy$10.00N/A
i
Rating by Madhu Kumar at Chardan Capital
9/29/2016Cantor FitzgeraldReiterated RatingBuy$15.00N/A
i
Rating by elemer piros at Cantor Fitzgerald
9/7/2016Chardan CapitalReiterated RatingBuy$10.00N/A
i
8/19/2016William BlairInitiated CoverageOutperformN/A
i
Rating by Y. Xu at William Blair
8/17/2016Cantor FitzgeraldInitiated CoverageBuy$15.00N/A
i
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$13.00 ➝ $8.00N/A
i
5/19/2016Chardan CapitalInitiated CoverageBuy$12.00N/A
i
Rating by M. Kumar at Chardan Capital
5/11/2016Jefferies Financial GroupReiterated RatingHold$4.75N/A
i
(Data available from 4/21/2016 forward)
Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $68.57
$66.85
$68.58

50 Day Range

MA: $67.78
$61.35
$83.78

52 Week Range

Now: $68.57
$30.83
$92.60

Volume

3,021 shs

Average Volume

800,017 shs

Market Capitalization

$7.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Arrowhead Pharmaceuticals?

The following equities research analysts have issued research reports on Arrowhead Pharmaceuticals in the last twelve months: B. Riley, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, TheStreet, and UBS Group AG.
View the latest analyst ratings for ARWR.

What is the current price target for Arrowhead Pharmaceuticals?

13 Wall Street analysts have set twelve-month price targets for Arrowhead Pharmaceuticals in the last year. Their average twelve-month price target is $85.31, suggesting a possible upside of 25.2%. Citigroup Inc. has the highest price target set, predicting ARWR will reach $110.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $34.00 for Arrowhead Pharmaceuticals in the next year.
View the latest price targets for ARWR.

What is the current consensus analyst rating for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARWR will outperform the market and that investors should add to their positions of Arrowhead Pharmaceuticals.
View the latest ratings for ARWR.

What other companies compete with Arrowhead Pharmaceuticals?

How do I contact Arrowhead Pharmaceuticals' investor relations team?

Arrowhead Pharmaceuticals' physical mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company's listed phone number is 626-304-3400 and its investor relations email address is [email protected] The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.